Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

EMD SERONO

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome

Phase 3

Completed

Conditions: Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome

Interventions: Biological: Serostim

First Posted Date: 2010-03-01

Last Posted Date: 2013-08-07

Lead Sponsor: EMD Serono

Target Recruit Count: 126

Registration Number: NCT01077960

Locations: 🇺🇸
University of Alabama/Birmingham, Birmingham, Alabama, United States
🇺🇸
Care Clinic, Los Angeles, California, United States
🇺🇸
Private Practice, Spokane, Washington, United States

and more 18 locations

EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2

Completed

Conditions: Squamous Cell Carcinoma of the Head and Neck Cancer

Interventions: Drug: Cetuximab
Drug: EMD 1201081

First Posted Date: 2009-12-30

Last Posted Date: 2017-01-30

Lead Sponsor: EMD Serono

Target Recruit Count: 107

Registration Number: NCT01040832

Locations: 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸
University of Kentucky, Markey Cancer Center, Lexington, Kentucky, United States
🇺🇸
MGH Massachusetts General Hospital, Boston, Massachusetts, United States

and more 19 locations

A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study

Phase 3

Completed

Conditions: Multiple Sclerosis

First Posted Date: 2009-12-21

Last Posted Date: 2013-08-08

Lead Sponsor: EMD Serono

Target Recruit Count: 103

Registration Number: NCT01036165

Locations: 🇺🇸
EMD Serono, Inc., Rockland, Massachusetts, United States

r-hGH Liquid Multidose Versus Freeze-dried Multidose Bioequivalence Trial

Phase 1

Completed

Conditions: Growth Hormone Deficiency
Growth Failure

Interventions: Biological: r-hGH liquid (Saizen)
Biological: r-hGH freeze-dried

First Posted Date: 2009-12-17

Last Posted Date: 2013-10-23

Lead Sponsor: EMD Serono

Target Recruit Count: 30

Registration Number: NCT01034735

Locations: 🇩🇪
AAI Pharma Deutschland GmbH & Co. KG, Neu-Ulm, Germany

The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial

Phase 4

Completed

Conditions: Relapsing Multiple Sclerosis

Interventions: Other: Blood sampling

First Posted Date: 2009-12-17

Last Posted Date: 2014-03-10

Lead Sponsor: EMD Serono

Target Recruit Count: 324

Registration Number: NCT01034579

Locations: 🇺🇸
Please Contact U.S. Medical Information Located in, Rockland, Massachusetts, United States

Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer

Phase 1

Completed

Conditions: Pancreatic Adenocarcinoma

Interventions: Drug: Pimasertib
Drug: Gemcitabine
Drug: Placebo

First Posted Date: 2009-11-19

Last Posted Date: 2017-07-13

Lead Sponsor: EMD Serono

Target Recruit Count: 141

Registration Number: NCT01016483

Locations: 🇺🇸
For Recruiting Locations in the United States, please Contact U.S. Medical Information, Rockland, Massachusetts, United States
🇩🇪
For Recruiting Locations outside the United States, Please contact the Merck KGaA Communication Center, Darmstadt, Germany

First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available

Interventions: Drug: MSC2156119J

First Posted Date: 2009-11-17

Last Posted Date: 2022-08-24

Lead Sponsor: EMD Serono

Target Recruit Count: 149

Registration Number: NCT01014936

Locations: 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States

Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants Who Have Participated in Cladribine Clinical Trials

Completed

Conditions: Multiple Sclerosis

First Posted Date: 2009-11-13

Last Posted Date: 2019-11-15

Lead Sponsor: EMD Serono

Target Recruit Count: 1161

Registration Number: NCT01013350

Locations: 🇺🇸
Outcome Sciences, Inc, Cambridge, Massachusetts, United States

The Multicenter, Open-label, Single-use Autoinjector Convenience Study

Phase 3

Completed

Conditions: Multiple Sclerosis

First Posted Date: 2009-08-13

Last Posted Date: 2013-08-07

Lead Sponsor: EMD Serono

Target Recruit Count: 109

Registration Number: NCT00958009

Locations: 🇺🇸
EMD Serono, Inc., Rockland, Massachusetts, United States

Trial of Pimasertib in Hematological Malignancies

Phase 2

Terminated

Conditions: Leukemia, Myeloid, Acute
Hematologic Neoplasms

Interventions: Drug: Pimasertib

First Posted Date: 2009-08-12

Last Posted Date: 2017-08-21

Lead Sponsor: EMD Serono

Target Recruit Count: 81

Registration Number: NCT00957580

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy